(NASDAQ: NXTC) Nextcure's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.7%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.83%.
Nextcure's earnings in 2025 is -$49,523,000.On average, 3 Wall Street analysts forecast NXTC's earnings for 2025 to be -$42,825,846, with the lowest NXTC earnings forecast at -$45,723,663, and the highest NXTC earnings forecast at -$39,552,390. On average, 2 Wall Street analysts forecast NXTC's earnings for 2026 to be -$40,113,394, with the lowest NXTC earnings forecast at -$49,089,685, and the highest NXTC earnings forecast at -$31,136,869.
In 2027, NXTC is forecast to generate -$25,807,101 in earnings, with the lowest earnings forecast at -$25,807,101 and the highest earnings forecast at -$25,807,101.